Stonebridge House
Chelmsford Road Hatfield Heath
England CM22 7BD
United Kingdom
https://www.valirx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. | CEO & Director | 183.35k | N/A | 1978 |
Mr. James Gerry Desler FCA | CFO, Company Secretary & Executive Director | 78.81k | N/A | 1945 |
Mr. Kumar Nawani | Head of Operations | N/A | N/A | N/A |
Dr. Catherine Jane Tralau-Stewart Ph.D. | Executive Director, Chief Scientific Officer & Board Officer | N/A | N/A | N/A |
Mr. Mark Treharne | Corporate Development Manager | N/A | N/A | N/A |
Dr. Andrew Carnegie | Head of Strategic Commercial Development | N/A | N/A | N/A |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
ValiRx plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.